Prednisone 5mg / 10mg / 20mg (Deltasone Generic)
Clinical guidance, bioequivalence criteria, and verified partner dispensing standards for Prednisone 5mg / 10mg / 20mg (Deltasone Generic). Reviewed by board-certified internal medicine and clinical pharmacotherapy specialists.
1. Clinical Dosing & Titration Protocols
Daily / Baseline Regimen
Acute Inflammatory Flares / Asthma Exacerbation: 20 mg to 60 mg daily for 5 to 7 days (burst therapy). Chronic Autoimmune Maintenance: 5 mg to 10 mg once daily in the morning.
On-Demand / Titration Regimen
Always take in the early morning with breakfast to mimic the body's natural circadian cortisol peak and prevent insomnia.
Courses lasting >2 weeks require a gradual dose taper to prevent secondary adrenal insufficiency.
2. Patient Administration & Safe Usage Guidelines
Take with breakfast or milk. Never stop abruptly if you have been taking prednisone for more than 14 days; follow a gradual taper.
Clinical Practice & Formulary Guidelines for Prednisone 5mg / 10mg / 20mg (Deltasone Generic)
Westover Hills Clinic provides evidence-based pharmacological reviews, bioequivalence assessments, and clinical monitoring recommendations for chronic disease management.
3. Frequently Asked Patient Questions
Why must Prednisone be taken in the morning?
Human adrenal cortisol production peaks naturally between 06:00 and 08:00 AM. Morning administration synchronizes with this circadian rhythm, minimizing pituitary-adrenal suppression and insomnia.
How does Prednisone convert to Prednisolone?
Prednisone is an inactive pro-drug. The hepatic enzyme 11-beta-hydroxysteroid dehydrogenase type 1 converts it into biologically active prednisolone within 1 hour.
4. Pharmacological Mechanism & Receptor Profile
Potent systemic glucocorticoid pro-drug that converts in the liver to prednisolone, suppressing pro-inflammatory cytokine transcription in severe autoimmune and inflammatory conditions.
Rheumatology & Internal Therapeutics • Prednisone 5mg / 10mg / 20mg (Deltasone Generic)
5. Chemical & Human Pharmacokinetic Matrix (Tmax, Half-Life, CYP450)
| Pharmacokinetic Parameter | Clinical Metric | Therapeutic Significance |
|---|---|---|
| Peak Plasma Time (Tmax) | 1.0 to 2.0 hours | Determines latency from ingestion to peak pharmacological onset. |
| Elimination Half-Life (T½) | 2.5 to 3.5 hours (plasma); tissue biological effect lasts 18–36 hours | Governs duration of action and steady-state dosing intervals. |
| Peak Concentration (Cmax) | Dose-dependent | Maximum observed systemic concentration in human plasma. |
| Bioavailability & Food Interaction | 80% to 100% | Defines oral bioavailability and dietary lipid dependency. |
| Plasma Protein Binding | 70% to 90% (bound to transcortin and albumin) | Governs free circulating drug fraction available for receptor binding. |
| Volume of Distribution (Vd) | 0.6 to 0.8 L/kg | Reflects tissue and lipid compartment penetration. |
| Hepatic Metabolism | Hepatic 11-beta-HSD1 reduction to active prednisolone, followed by CYP3A4 | Primary enzymatic clearance and CYP pathways. |
| Elimination / Excretion | Excreted primarily in urine as sulfate and glucuronide conjugates | Renal vs biliary/fecal excretion balance. |
6. Drug-Drug Interaction Matrix
| Interacting Agent / Class | Severity Tier | Clinical Mechanism & Management Strategy |
|---|---|---|
| NSAIDs (Ibuprofen, Naproxen) | Major Precaution | Synergistic increase in peptic ulceration and gastrointestinal bleeding. |
| Antidiabetic Agents / Insulin | Dose Adjustment | Glucocorticoids induce hepatic gluconeogenesis and elevate blood glucose. |
7. Adverse Reaction Profile & Clinical Incidence Rates
| Adverse Reaction | Incidence Rate | Physiological Mechanism & Mitigation Strategy |
|---|---|---|
| Insomnia & Increased Energy | 20% | Mitigated by taking entire dose in the morning before 09:00 AM. |
| Increased Appetite & Fluid Retention | 15% | Cortisol-mediated metabolic response. |
| Hyperglycemia | 12% | Transient insulin resistance. |
Peer-Reviewed Scientific Citations & FDA References
- Fardet L, et al. Corticosteroid-induced adverse events: a review. Drug Saf. 2007;30(10):861-881.